Logo BcnPit

Barcelona – Pittsburgh

XII Biennial Conference Barcelona Pittsburgh
1st to 3rd June 2022
All day
Streaming Online
La Pedrera
Register

Welcome to the XII Biennial Conference Barcelona – Pittsburgh!

You are joining a conference that has become a reference in the field of dementia. This year, on June 2022, BCNPIT will emerge again as a valuable forum where professionals from all over the globe connect and share their work and prospects about dementia.

This is a high-quality conference that brings together panellists of recognized international scientific prestige and creates and interactive space related to neuroscience which ultimate objective is to benefit the people affected and their families.

BARCELONA-PITTSBURGH PRESENTIAL

The most complete academic event of the year. 3 days of networking & sharing knowledge with speakers and attendees in an exclusive venue in Barcelona. Full access to the recorded lectures during the next month of the conference. For those who want to fully immerse themselves in the latest advances in dementia.

600€ + IVA
Get your ticket

BARCELONA-PITTSBURGH ONLINE

Don’t miss any of the speakers, materials, presentations and much more. Enjoy the conference wherever you are. Full access during the next month of the conference.

400€ + IVA
Get your ticket

UNIQUE EVENT: THE FUTURE OF RESEARCH

Auditori Grifols (Sant Cugat del Vallès)

An online exclusive one-hour event about genome research in the field of dementia: facts, figures and what the future holds.

If you wish to attend in-person, please send an email to bcnpit@fundacioace.org

Limited seating capacity

FREE – GET YOUR CODE

Speakers

Currently, Dr. Costa is Director of Plasma Proteins Research of the Grifols Bioscience Research Group, where she is in charge of leading Alzheimer’s Disease research.

Montse Costa, PhD Director of the Plasma Proteins Research at the R&D Grifols

Head Neurodegeneration Development Unit at Biogen

Samantha Budd Haeberlein Head Neurodegeneration Development Unit at Biogen

Clinical Research Sr Manager at Araclon Biotech

Elisabet Molina, MSc Clinical Research Sr Manager at Araclon Biotech

He is particularly interested in bridging biomedical research with drug development by adapting novel technologies to target identification/validation- and screening programs.

Alfredo Cabrera, PhD Senior Scientist at Janssen

Dr. Montaner’s clinical and laboratory work focuses on the identification of biomarkers to be used as diagnostic and prognostic tools in ischemic and haemorrhagic stroke and also as companion diagnostics for several stroke therapies.

Joan Montaner Director of the Stroke Program at the Institute of Biomedicine of Seville (IBiS)

At Ace, he design CTs and other global CT from pharmaceutical companies, participate in international boards to improve CT management and promote research projects to validate novel biomarkers for an early detection of the disease and find novel therapeutical approaches.

Xavier Morató, PhD Pharmacy Unit at Ace

The main focus of Prof. Ramirez research is the identification of the molecular genetic mechanisms which underlie cognitive disorders including neurodegenerative dementias such as Alzheimer’s disease.

Prof. Alfredo Ramírez, MD, PhD Professor for Neurogenetics of Cognitive disorders at the University Hospital Cologne

As a clinician he has a longstanding expertise in translational research, focusing on how to improve individual diagnostics and therapy of disorders of the nervous system and how to define most reliable brain activations in pathological brains.

Roland Beisteiner, MD Associate Professor the Medical University of Vienna

Prof. Arcadi Navarro, biologist, ICREA professor and researcher at the Department of Experimental and Health Sciences at UPF, Director of the Pasqual Maragall Foundation and Barcelonaβeta Brain Research Center

Arcadi Navarro, PhD Director at Fundación Pasqual Maragall

In addition to his research work at the BarcelonaBeta Brain Research Center, Dr. Suárez-Calvet is a clinical neurologist at the Hospital del Mar (Barcelona), specializing in Alzheimer’s disease and other neurodegenerative diseases.

Marc Suárez-Calvet, MD, PhD Neurologist at BarcelonaBeta Brain Research Center

Dr. Kiprov’s recent scientific and clinical work focuses on the role of Therapeutic Plasma Exchange (TPE) in the Treatment and Prevention of Age Related Disorders.

Dobri Kiprov, MD, HP Owner at Global Apheresis

Dr. Alberto Lleó has combined his clinical activity with translational research projects in the field of dementias with a specific focus on the molecular bases of the disease and biomarker development.

Alberto Lleó, MD, PhD Director of the Neurology Department at Hospital de la Santa Creu i Sant Pau

Università degli Studi di Brescia

Andrea Pilotto

Dr. Butler research focusses on understanding the memory deficits experienced by patients with damage to the medial temporal lobes of the brain

Chris Butler, MD, PhD Clinical Senior Lecturer in Neurology at the Imperial College

The Kristel Sleegers lab is committed to increase insight in the complex genetics of Alzheimer’s disease and to investigate the translational potential of genetic discovery.

Kristel Sleegers, MD, PhD Full professor of Genetic Neuroepidemiology at the University of Antwerp

The Neurochemistry Laboratory of VUmc aims at developing biomarkers for neurodegenerative diseases.

Charlotte Teunissen, PhD Professor in Neurochemistry at VUmc

Dr. Ikram’s research focuses on investigating the etiology of neurologic diseases in the elderly, with a particular focus on dementia, Alzheimer disease, stroke, and Parkinson disease.

Arfan Ikram, MD, PhD Professor and Chair Epidemiology at the Erasmus University Medical Center

His landmark study on cerebrospinal fluid biomarkers for Alzheimer’s disease from 2006 (Hansson et al, The Lancet Neurology, 2006) has been instrumental for the implementation of these biomarkers in the clinical work-up of Alzheimer’s disease in Sweden and internationally.

Oskar Hansson, MD, PhD Professor of Neurology at Lund University

Vitorica’s group main goal is the characterization of transgenic mice models of AD at the cellular and molecular levels.

Javier Vitorica, PhD Principal researcher at Ciberned

Dr. Cohen’s research interests include aging, Alzheimer’s disease and neuroimaging.

Ann D Cohen, PhD Associate Professor at the University of Pittsburgh

Dr. Hinzen study the structural organization and function of language in the human mind/brain.

Wolfram Hinzen, PhD ICREA Research Professor at UPF

Dr. Debette studies the specific genetic markers in the structuring of the brain in young adults, using magnetic resonance imaging as part of the i-Share study.

Stéphanie Debette, MD, PhD Professor of Epidemiology and Neurologist at Université de Bordeaux

Dr. Lopez’s clinical interests include cognitive disorders of multiple etiologies, and his research interests include clinical symptoms and progression of Alzheimer’s disease and other dementias, biomarkers, and risk factors for Alzheimer’s disease in cognitively normal persons.

Oscar López, MD Director of the Alzheimer's Disease Research Center at the University of Pittsburgh

Dr. Vellas main interests are: development of aging and geriatric clinical research and care.

Bruno Vellas, MD, PhD Department of Geriatric Internal Medicine at the Toulouse University Hospital

Dr. Sasha Bozeat is responsible for the medical support of the commercially available Elecsys AD CSF assays, as well as the blood-based biomarker pipeline at Roche Diagnostics

Sasha Bozeat, PhD Senior International Medical Manager at Roche Diagnostics

His research is centered in understanding different aspects of the inflammatory reaction.

Prof. Santos Mañes, PhD Full Professor at the National Center for Biotechnology (CSIC)

Prof. Heneka is involved in basic science and translational research with focus on neurodegeneration and neuroinflammation.

Prof. Michael Heneka, MD Director of the Luxembourg Centre for Systems Biomedicine

Dr. Van der Lee is particularly interested to translate findings from basic science to clinically useful (bio)markers of dementia

Sven van der Lee, MD, PhD Postdoctoral Researcher

Dr. Seshadri enjoys a superb reputation in both science and clinical care and is a recognized thought leader in Alzheimer’s disease.

Sudha Seshadri, MD Founding director of the Glenn Biggs Institute for Alzheimer's & Neurodegenerative Diseases

Dr. Boada focuses her research on the treatment of AD and related dementias, especially on the genotype and phenotype of common degenerative diseases and the design of new pharmacological and non-pharmacological treatments.

Prof. Mercè Boada, MD, PhD Chief Medical Officer at Ace

Dr. Zlokovic studies the role of brain microcirculation, particularly the blood-brain barrier (BBB) in health and disease in the adult brain and during brain aging.

Berislav V Zlokovic, MD, PhD Director of the Zilkha Neurogenetic Institute

Dr. Cano is in charge of the molecular biology unit of Ace Alzheimer Center Barcelona and her studies are related to the clinical evaluation of early biomarkers of Alzheimer’s disease.

Amanda Cano, PhD Postdoctoral researcher at Ace

The main objective of his genomic research group is to understand the causes of Alzheimer’s disease and other dementias by integrating genetic, transcriptomic and proteomic data.

Agustín Ruiz, MD, PhD Chief Scientific Officer at Ace

Focused on translational research with a utility approach to the patient and on providing scientific evidence on the diagnosis in early and preclinical phases of Alzheimer’s disease

Pascual Sánchez Juan, MD, PhD Scientific Director of CIEN Foundation

Experience in the cognitive assessment of patients with neurological diseases using different neuropsychological tools, neuroimaging analysis (brain MRI and PET), and in the use of Transcranial Magnetic Stimulation using neuronavigator for the treatment of patients with neurodegenerative diseases.

Vanesa Pytel, MD, PhD Clinical Head of the Diagnostic Unit at Ace

Dr. Alegret has extensive experience in diagnosis, clinical management, neuropsychological evaluation, cognitive stimulation and research on different neurodegenerative diseases

Montse Alegret, PhD Neuropsychologist at Ace

Neurologist specialist in cognitive disorders with a broad clinical and research experience in Spain and the United States.

Marta Marquié, MD, PhD Neurologist at Ace

He has more than 20 years of experience in basic, clinical and applied research in drug dependence, psychopathology and memory disorders.

Sergi Valero, PhD Head of Medical Psychology at Ace Alzheimer Center Barcelona

Dr. Villemagne is a physician scientist in full-time research specialising in the development of molecular biomarkers for discovery, diagnosis, prognosis and clinical trials in neurodegenerative diseases.

Victor L Villemagne, MD Professor of Psychiatry at the University of Pittsburgh

SPEAKER’S AREA

In order to make the communication with the congress staff easy for you, enter to the speaker’s area and find all the information you need
PROGRAM
Unique event
19:00 h.
19:00 h.
Delivered by Grifols, La Caixa and Ace Alzheimer Center Barcelona representatives
6th Joan Boada & Mercè Rovira Award
19:30 h.
19:30 h.
In collaboration with Fundació Castell de Peralada
Research workshop: Alzheimer’s dancing
Cocktail
Registration
8:30 h. - 8:55 h.
8:30 h. - 8:55 h.
Keynote Lecture
Innovations in neurodegenerative biomarker research
8:55 h. - 9:25 h.
PANEL
INNOVATIVE BIOMARKER RESEARCH
8:55 h. - 9:10 h.
8:55 h. - 9:10 h.
Changing the scenario for clinical research and trial design: the evaluation of new biomarkers in cerebrospinal fluid and plasma of patients with neurodegenerative disorders
9:10 h. - 9:25 h.
9:10 h. - 9:25 h.
Diagnostic potential of biomarkers loaded in plasma-derived exosomes in a cohort of early-onset mild cognitive impairment: the BIOFACE study
9:25 h. - 9:50 h.
9:25 h. - 9:50 h.
Keynote Lecture
Applications and methodological challenges of plasma biomarkers for dementia research
9:50 h. - 10:20 h.
PANEL
PLASMA BIOMARKERS
9:50 h. - 10:05 h.
9:50 h. - 10:05 h.
Plasma biomarkers for AT(N) classification of neurodegenerative dementias.
10:05 h. - 10:20 h.
10:05 h. - 10:20 h.
Blood-based biomarkers in the Alzheimer's continuum
10:20 h. - 10:45 h.
10:20 h. - 10:45 h.
Discussion with all panellist
Coffee break
11:15 h. - 11:40 h.
11:15 h. - 11:40 h.
Keynote Lecture
Blood-Brain Barrier Role in Neurodegeneration, Cognitive Decline and Alzheimer’s Disease
11:45 h. - 12:15 h.
PANEL
BLOOD-BRAIN BARRIER AND NEUROVASCULAR HYPOTHESES
11:45 h. - 12:00 h.
11:45 h. - 12:00 h.
Blood-Brain Barrier opening in neurodegenerative diseases: possibilities and limitations
12:00 h. - 12:15 h.
12:00 h. - 12:15 h.
Are vascular risk factors really associated with neurodegenerative diseases?
12:15 h. - 12:35 h.
12:15 h. - 12:35 h.
Keynote Lecture
Microglia – neuron interaction through tunneling nanotubes
12:35 h. - 13:05 h.
PANEL
NEUROINFLAMMATORY HYPOTHESES FOR NEURODEGENERATIVE DISEASES
12:35 h. - 12:50 h.
12:35 h. - 12:50 h.
Using human induced pluripotent stem cells to improve drug development in neuroscience
12:50 h. - 13:05 h.
12:50 h. - 13:05 h.
Microglial dysfunction in Alzheimer pathology
13:05 h. - 13:30 h.
13:05 h. - 13:30 h.
Introduced by Ace Alzheimer Center Barcelona & University of Pittsburgh representatives
OPENING SESSION
LUNCH
14:30 h. - 14:50 h.
14:30 h. - 14:50 h.
Keynote Lecture
Paradigm Shift in the Utilization of Plasmapheresis in Clinical Practice
14:50 h. - 15:20 h.
PANEL
PERIPHERAL INTERVENTIONS IN AD
14:50 – 15:05
14:50 – 15:05
Learnings from AMBAR to the real world
15:05 – 15:20
15:05 – 15:20
AMBAR: a multimechanistic intervention for a multicausal disease
15:20 h. - 15:45 h.
15:20 h. - 15:45 h.
Keynote Lecture
Genetics in the 'Memory' Clinic: Current and Emerging Roles in Prevention, Diagnosis and Drug Discovery
15:45 h. - 16:15 h.
15:45 h. - 16:00 h.
15:45 h. - 16:00 h.
The many ways to longevity: Polygenic Risk Scores in CHARGE and beyond
16:00 h. - 16:15 h.
16:00 h. - 16:15 h.
Genomics of cerebral small vessel disease and implications for AD and dementia
Coffee break
16:45 h. - 17:10 h.
16:45 h. - 17:10 h.
Keynote Lecture
Genetics of Alzheimer’s disease: 15 years of discoveries using genomewide scans (GWAS)
17:10 h. - 17:40 h.
17:10 h. - 17:25 h.
17:10 h. - 17:25 h.
Adding dynamics to genetic modulators of Alzheimer's disease susceptibility
17:25 h. - 17:40 h.
17:25 h. - 17:40 h.
The interface of genomics and transcriptomics in Alzheimer's disease
17:40 h. - 18:00 h.
17:40 h. - 18:00 h.
Keynote Lecture
Speech biomarker
18:00 h. - 18:30 h.
PANEL
APP, E-COHORTS, PRECISION MEDICINE & TELEMEDICINE
18:00 h. - 18:15 h.
18:00 h. - 18:15 h.
Ace digital biomarkers: Facememory® approach
18:15 h. - 18:30 h.
18:15 h. - 18:30 h.
Precision Medicine in AD
Registration
9:00 - 9:20
9:00 - 9:20
Keynote Lecture
The WHO ICOPE program and early diagnosis of Alzheimer
9:20 - 9:40
9:20 - 9:40
Keynote Lecture
Prediction of dementia by blood and PET biomarkers change over a period of 10 years
9:40 - 10:10
9:40 - 10:10
Keynote Lecture
Molecular imaging of amyloid, tau and neuroinflammation in Alzheimer’s disease.
10:10 - 10:40
PANEL
MOLECULAR NEUROIMAGING
10:10 - 10:25
10:10 - 10:25
Amyloid PET in Subjective Cognitive Decline: experience from the FACEHBI cohort
10:25 - 10:40
10:25 - 10:40
Integrating standard and novel MRI measures to measure neurodegeneration and cerebrovascular disease across the spectrum of AD
Coffee Break
11:15 – 11:45
PANEL
NEUROSTIMULATION
11:15 - 11:30
11:15 - 11:30
Transcranial magnetic stimulation: a new approach to treat neurodegenerative diseases
11:30 - 11:45
11:30 - 11:45
Transcranial Ultrasound Stimulation: a novel method for non-invasive brain stimulation in health and disease
11:45 - 12:05
11:45 - 12:05
Keynote Lecture
Transcranial Pulse Stimulation TPS - a novel add on therapy for neurodegeneration
12:05 - 12:30
12:05 - 12:30
Keynote Lecture
Overview of global Pipelines
12:30 - 13:50
PANEL
THERAPEUTIC ADVANCES IN AD
12:30 – 12:50
12:30 – 12:50
Development of therapeutics in Alzheimer’s disease
12:50 – 13:10
12:50 – 13:10
Plasma Biomarker Effects of ALZ-801 in APOE4 Carriers with Early AD: Phase 2 Study Interim Results
13:10 – 13:30
13:10 – 13:30
Top line data phase 2 study of ABvac40, an active vaccine anti-Aβ40 in patients with mild cognitive impairment or very-mild Alzheimer’s disease
13:30 – 13:50
13:30 – 13:50
Lessons learned: Developing gantenerumab as an Alzheimer's disease modifying therapy
13:50 – 14:15
13:50 – 14:15
Introduced by Ace Alzheimer Center Barcelona & University of Pittsburgh representatives
CLOSING CEREMONY

Sponsors

Platinum
Silver
Bronze
Sponsor
Other collaborators
Barcelona-Pittsburgh Conference
Pg. de Gràcia, 92, 08008 Barcelona Direcciones en Google Maps

Don’t miss the opportunity to be part of one of the largest communities in the field of dementia. Join the XII Biennial Conference Barcelona Pittsburgh

BcnPit Registro